Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Allergologia Et Immunopathologia|September 15, 2024
Knockdown of OLFM4 protects cardiomyocytes from sepsis by inhibiting apoptosis and inflammatory responsesHailu Chen, Shuna Liu, Guihua Fang
Healthcare (Basel, Switzerland)|October 16, 2024
Multi-Regional Pelvic Floor Muscle Function Diagnosis System Based on Inflatable Stretchable Electrode ArrayHailu Chen, Siming Wu, Yinfeng Wang, et al.
Journal of Chromatography. A|October 8, 2021
Advantages of rectangular horizontal tubing in the semi-preparative counter-current chromatography bobbinShunjie Zhang, Haijun Chen, Xiaodie Deng, et al.
Journal of Chromatography. A|September 29, 2019
Visualization of Type-J counter current chromatography: Hydrodynamic behavior in a helical columnTao Tang, Haijun Chen, Xiaodie Deng, et al.
Journal of Chromatography. A|February 27, 2020
Modeling counter-current chromatography with non-ideal injectionHaijun Chen, Jianfeng Chen, Tao Tang, et al.
Advances in Therapy|June 15, 2024
Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: NEDA-3 After Re-Baselining in the Phase 3 EVOLVE-MS-1 StudyJames D Bowen, Jessica Stulc, Samuel F Hunter, et al.
Medical Oncology (Northwood, London, England)|December 7, 2014
Postoperative adjuvant therapy for resectable thoracic esophageal squamous cell carcinoma: a retrospective analysis of 426 casesHailu Chen, Zhiyong Wu, Jiexin Chen, et al.
Therapeutic Advances in Neurological Disorders|April 2, 2021
Improved gastrointestinal profile with diroximel fumarate is associated with a positive impact on quality of life compared with dimethyl fumarate: results from the randomized, double-blind, phase III EVOLVE-MS-2 studyAnnette Wundes, Sibyl Wray, Ralf Gold, et al.
Neurology and Therapy|June 27, 2024
Lymphopenia is Not the Primary Therapeutic Mechanism of Diroximel Fumarate in Relapsing-Remitting Multiple Sclerosis: Subgroup Analyses of the EVOLVE-MS-1 StudyBarry A Singer, Sibyl Wray, Mark Gudesblatt, et al.
CNS Drugs|January 19, 2020
Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 StudyRobert T Naismith, Annette Wundes, Tjalf Ziemssen, et al.
Pageof 2